Autoimmune Disorders Therapeutics Market to 2017 - Launch of Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis and Systemic Lupus Erythematosus Therapeutic Segments

Document Sample
Autoimmune Disorders Therapeutics Market to 2017 - Launch of Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis and Systemic Lupus Erythematosus Therapeutic Segments Powered By Docstoc
					         Autoimmune Disorders Therapeutics Market to 2017 -
         Launch of Gilenya and Benlysta to Drive the Growth of
         Multiple Sclerosis and Systemic Lupus Erythematosus
                         Therapeutic Segments
 Reference Code: GBIHC147MR                                                                                                  Publication Date: April 2012


                                     Autoimmune Disorders Therapeutics Market Becoming Increasingly Attractive due to
                                     Continuous Growth
                                       Autoimmune Disorders Therapeutics Market, Global, Revenue Forecasts ($bn), 2002–2017

                                                               70


                                                                                                 CAGR (2010-2017): 10.7%
                                                               60



                                                               50
                                               Revenue ($bn)




                                                               40
                                                                    CAGR (2002-2010): 7.5%


                                                               30



                                                               20



                                                               10



                                                                0
                                                                           2002                          2010                         2017


                                       Source: GBI Research, DrugBank, Company’s Annual Reports, The US Patent and Trademark Office, RxUSA




                                     The autoimmune disorders therapeutics market, comprising six major indications, was worth $16.9
                                     billion in 2002 and grew at a Compound Annual Growth Rate (CAGR) of 7.5% to $30.2 billion in
                                     2010. It is forecast to reach $61.4 billion in 2017, indicating a CAGR of 10.7% during the forecast
                                     period. The average Annual Cost of Treatment (ACT) for autoimmune disorders therapeutics is
                                     increasing, and is expected to reach $12,073 by 2017, resulting in steady increase of the overall
                                     market during the forecast period.
                                     Launch of Benlysta will Significantly Boost the Systemic Lupus Erythematosus Disease
                                     Therapeutics Market
                                     Benlysta is the first new drug to have been approved by the Food and Drug Administration (FDA)
                                     and launched in the Systemic Lupus Erythematosus (SLE) disease therapeutics sector within the
                                     past five decades. It was launched in the US market in April 2011, and is expected to be launched
                                     in the European market very soon. Sales of Benlysta are projected to reach $3.5 billion by 2014
                                     and $14.2 billion by 2017.




Autoimmune Disorders Therapeutics Market to 2017 - Launch of                                                              GBIHC147MR /Published APR 2012
Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis                                                                                          Page 1
and Systemic Lupus Erythematosus Therapeutic Segments                                © GBI Research. This report is a licensed product and is not to be copied,
                                                                                                                     reproduced, shared or resold in any form
                                     Rheumatoid Arthritis and Multiple Sclerosis Molecules Account for 59% of the Global
                                     Autoimmune Disorders Therapeutics Pipeline
                                     The autoimmune disorders therapeutics market scenario demands substantial output from
                                     pharmaceutical companies’ Research and Development (R&D) departments. With a series of
                                     patent expiries due in the forecast period, the six main autoimmune indications are set to lose
                                     billions of dollars of revenue as a result. The pipeline for the autoimmune disorders therapeutics
    In late 2010, the R&D            market holds a number of promising molecules those are expected to replace the revenue lost from
    pipeline for autoimmune          the aforementioned patent expiries.
    disorders had                    In late 2010, the R&D pipeline for autoimmune disorders had approximately 887 programs in
    approximately 887                different stages of discovery and development
    programs in different
                                       Autoimmune Disorders Therapeutics Market, Global, R&D Pipeline by Indication (%), 2011
    stages of discovery and
    development.
                                                                                     Ulcerative       Crohn's
                                                                                       Colitis        Disease
                                                                                 SLE    8%             10%
                                                                                 6%



                                                                                                                    Multiple Sclerosis
                                                                                                                           22%




                                                          Rheumatoid Arthritis                                   Psoriasis
                                                                37%                                                17%


                                       Source: GBI Research, Company Websites, ClinicalTrials.gov




                                     The Rheumatoid Arthritis (RA) R&D pipeline accounted for 37% of the overall pipeline in 2011,
                                     followed by Multiple Sclerosis (MS) and psoriasis with 22% and 17% respectively. This is followed
                                     by Crohn's Disease (CD), with 10%, and Ulcerative Colitis (UC) and SLE with 8% and 6%
                                     respectively.




Autoimmune Disorders Therapeutics Market to 2017 - Launch of                                                      GBIHC147MR /Published APR 2012
Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis                                                                                  Page 2
and Systemic Lupus Erythematosus Therapeutic Segments                        © GBI Research. This report is a licensed product and is not to be copied,
                                                                                                             reproduced, shared or resold in any form
                                     1         Table of Contents
                                     1   Table of Contents ........................................................................................................................ 3
                                         1.1    List of Tables..................................................................................................................... 6
                                         1.2    List of Figures ................................................................................................................... 9
                                     2   Autoimmune Disorders Therapeutics Market to 2017 - Introduction .......................................... 12
                                         2.1    GBI Research Report Guidance ..................................................................................... 13
                                     3   Autoimmune Disorders Therapeutics Market to 2017 - Market Overview .................................. 14
                                         3.1    Introduction ..................................................................................................................... 14
                                            3.1.1    Revenue .................................................................................................................. 14
                                            3.1.2    Annual Cost of Treatment........................................................................................ 15
                                            3.1.3    Treatment Usage Pattern ........................................................................................ 16
                                     4   Autoimmune Disorders Therapeutics Market to 2017: Geographical Landscape ...................... 18
                                         4.1    Revenue Analysis by Geography .................................................................................... 18
                                         4.2    The US ............................................................................................................................ 19
                                            4.2.1    Revenue .................................................................................................................. 19
                                            4.2.2    Annual Cost of Treatment........................................................................................ 20
                                            4.2.3    Treatment Usage Patterns ...................................................................................... 21
                                         4.3    Top Five Countries of Europe ......................................................................................... 23
                                            4.3.1    Revenue .................................................................................................................. 23
                                            4.3.2    Revenue by Country ................................................................................................ 24
                                            4.3.3    Annual Cost of Treatment........................................................................................ 25
                                            4.3.4    Treatment Usage Patterns ...................................................................................... 26
                                         4.4    Japan .............................................................................................................................. 28
                                            4.4.1    Revenue .................................................................................................................. 28
                                            4.4.2    Annual Cost of Treatment........................................................................................ 29
                                            4.4.3    Treatment Usage Patterns ...................................................................................... 30
                                     5   Autoimmune Disorders Therapeutics Market to 2017: Therapeutic Landscape ........................ 32
                                         5.1    Rheumatoid Arthritis Therapeutics Market ...................................................................... 32
                                            5.1.1    Introduction .............................................................................................................. 32
                                            5.1.2    Revenue .................................................................................................................. 32
                                            5.1.3    Treatment Algorithm ................................................................................................ 36
                                            5.1.4    Annual Cost of Treatment........................................................................................ 36
                                            5.1.5    Treatment Usage Pattern ........................................................................................ 37
                                            5.1.6    Drivers and Barriers for the Rheumatoid Arthritis Therapeutics Market................... 39
                                         5.2    Multiple Sclerosis Therapeutics Market .......................................................................... 41
                                            5.2.1    Introduction .............................................................................................................. 41
                                            5.2.2    Revenue .................................................................................................................. 42
                                            5.2.3    Treatment Algorithm ................................................................................................ 46
                                            5.2.4    Annual Cost of Treatment........................................................................................ 47
                                            5.2.5    Treatment Usage Patterns ...................................................................................... 48
                                            5.2.6    Drivers and Barriers for Multiple Sclerosis Therapeutics Market ............................. 49
                                         5.3    Psoriasis Therapeutics Market ........................................................................................ 51
                                            5.3.1    Introduction .............................................................................................................. 51
                                            5.3.2    Revenue .................................................................................................................. 52
                                            5.3.3    Treatment Algorithm ................................................................................................ 55
                                            5.3.4    Annual Cost of Treatment........................................................................................ 55
                                            5.3.5    Treatment Usage Pattern ........................................................................................ 56
                                            5.3.6    Drivers and Barriers for Psoriasis Therapeutics Market .......................................... 58
                                         5.4    Inflammatory Bowel Disease Therapeutics Market ......................................................... 59
                                            5.4.1    Introduction .............................................................................................................. 59
                                            5.4.2    Revenue .................................................................................................................. 60
                                            5.4.3    Treatment Algorithm ................................................................................................ 63
                                            5.4.4    Annual Cost of Treatment........................................................................................ 65
                                            5.4.5    Treatment Usage Pattern ........................................................................................ 66
                                            5.4.6    Drivers and Barriers for the Inflammatory Bowel Disease Therapeutics Market ...... 68



Autoimmune Disorders Therapeutics Market to 2017 - Launch of                                                              GBIHC147MR /Published APR 2012
Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis                                                                                          Page 3
and Systemic Lupus Erythematosus Therapeutic Segments                                © GBI Research. This report is a licensed product and is not to be copied,
                                                                                                                     reproduced, shared or resold in any form
                                       5.5    Systemic Lupus Erythematosus Therapeutics Market .................................................... 69
                                          5.5.1    Introduction .............................................................................................................. 69
                                          5.5.2    Revenue .................................................................................................................. 70
                                          5.5.3    Treatment Algorithm ................................................................................................ 73
                                          5.5.4    Annual Cost of Treatment........................................................................................ 74
                                          5.5.5    Treatment Usage Pattern ........................................................................................ 75
                                          5.5.6    Drivers and Barriers for the Systemic Lupus Erythematosus Therapeutics Market . 78
                                     6 Autoimmune Disorders Therapeutics Market to 2017: Pipeline Analysis................................... 80
                                       6.1    Introduction ..................................................................................................................... 80
                                       6.2    Autoimmune Disorders Therapeutics Market – Pipeline Assessment by Clinical Phase of
                                              Development ................................................................................................................... 82
                                          6.2.1    Filed Molecules........................................................................................................ 82
                                          6.2.2    Phase III .................................................................................................................. 85
                                          6.2.3    Phase II ................................................................................................................. 107
                                          6.2.4    Phase I .................................................................................................................. 115
                                          6.2.5    Preclinical Phase ................................................................................................... 118
                                          6.2.6    Discovery Phase.................................................................................................... 126
                                       6.3    Profiles of Promising Molecules in the Autoimmune Disorders Therapeutics Market ... 128
                                          6.3.1    ABT-874 ................................................................................................................ 128
                                          6.3.2    Actemra ................................................................................................................. 128
                                          6.3.3    Biferonex ............................................................................................................... 129
                                          6.3.4    Fampyra ................................................................................................................ 130
                                          6.3.5    Iguratimod.............................................................................................................. 130
                                          6.3.6    LAS41002 .............................................................................................................. 131
                                          6.3.7    MAbThera .............................................................................................................. 132
                                          6.3.8    Rebif ...................................................................................................................... 133
                                          6.3.9    Remicade .............................................................................................................. 134
                                          6.3.10 Simponi ................................................................................................................. 135
                                          6.3.11 T-614 ..................................................................................................................... 136
                                          6.3.12 Zushima ................................................................................................................. 137
                                     7 Autoimmune Disorders Therapeutics Market to 2017: Competitive Profiling ........................... 138
                                       7.1    Market Share Analysis .................................................................................................. 138
                                       7.2    Competitive Profiling ..................................................................................................... 138
                                          7.2.1    Abbott Laboratories ............................................................................................... 138
                                          7.2.2    Pfizer Inc................................................................................................................ 139
                                          7.2.3    Johnson & Johnson ............................................................................................... 141
                                          7.2.4    Biogen Idec Inc. ..................................................................................................... 142
                                          7.2.5    Amgen Inc. ............................................................................................................ 143
                                          7.2.6    Bayer AG ............................................................................................................... 145
                                          7.2.7    Sanofi .................................................................................................................... 146
                                     8 Autoimmune Disorders Therapeutics Market to 2017: Strategic Consolidations ..................... 148
                                       8.1    Overview ....................................................................................................................... 148
                                       8.2    Mergers and Acquisitions .............................................................................................. 149
                                          8.2.1    Segmentation by Indication ................................................................................... 149
                                          8.2.2    Segmentation by Year ........................................................................................... 150
                                          8.2.3    Segmentation by Deal Type .................................................................................. 151
                                          8.2.4    Segmentation by Deal Value ................................................................................. 152
                                          8.2.5    Segmentation by Geography ................................................................................. 154
                                       8.3    Co-development Deals ................................................................................................. 155
                                          8.3.1    Segmentation by Indication ................................................................................... 155
                                          8.3.2    Segmentation by Year ........................................................................................... 156
                                          8.3.3    Segmentation by Value ......................................................................................... 157
                                          8.3.4    Segmentation by Geography ................................................................................. 158
                                          8.3.5    Summary of Co-development Deals ...................................................................... 161
                                       8.4    Licensing Deals............................................................................................................. 163
                                          8.4.1    Segmentation by Indication ................................................................................... 163


Autoimmune Disorders Therapeutics Market to 2017 - Launch of                                                             GBIHC147MR /Published APR 2012
Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis                                                                                         Page 4
and Systemic Lupus Erythematosus Therapeutic Segments                               © GBI Research. This report is a licensed product and is not to be copied,
                                                                                                                    reproduced, shared or resold in any form
                                          8.4.2   Segmentation by Year ........................................................................................... 164
                                          8.4.3   Segmentation by Value ......................................................................................... 165
                                          8.4.4   Segmentation by Geography ................................................................................. 166
                                          8.4.5   Summary of Licensing Deals ................................................................................. 173
                                     9 Autoimmune Disorders Therapeutics Market to 2017: Appendix ............................................. 176
                                       9.1    Market Definitions ......................................................................................................... 176
                                       9.2    Abbreviations ................................................................................................................ 176
                                       9.3    Sources ......................................................................................................................... 178
                                       9.4    Research Methodology ................................................................................................. 178
                                          9.4.1   Coverage ............................................................................................................... 179
                                          9.4.2   Secondary Research ............................................................................................. 179
                                          9.4.3   Primary Research .................................................................................................. 179
                                       9.5    Therapeutic Landscape ................................................................................................ 180
                                          9.5.1   Epidemiology-based Forecasting .......................................................................... 180
                                          9.5.2   Market Size by Geography .................................................................................... 182
                                       9.6    Geographical Landscape .............................................................................................. 183
                                       9.7    Pipeline Analysis ........................................................................................................... 183
                                       9.8    Competitive Landscape ................................................................................................ 183
                                       9.9    Expert Panel Validation................................................................................................. 183
                                       9.10 Contact Us .................................................................................................................... 183
                                       9.11 Disclaimer ..................................................................................................................... 183




Autoimmune Disorders Therapeutics Market to 2017 - Launch of                                                             GBIHC147MR /Published APR 2012
Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis                                                                                         Page 5
and Systemic Lupus Erythematosus Therapeutic Segments                               © GBI Research. This report is a licensed product and is not to be copied,
                                                                                                                    reproduced, shared or resold in any form
                                     1.1     List of Tables
                                     Table 1:    Autoimmune Disorders Therapeutics Market, Global, Revenue ($bn), 2002–2010 ....... 14
                                     Table 2:    Autoimmune Disorders Therapeutics Market, Global, Revenue Forecasts ($bn), 2010–
                                                 2017 ............................................................................................................................... 14
                                     Table 3:    Autoimmune Disorders Therapeutics Market, Global Annual Cost of Treatment ($),
                                                 2002–2010 ..................................................................................................................... 15
                                     Table 4:    Autoimmune Disorders Therapeutics Market, Global Annual Cost of Treatment ($),
                                                 2010–2017 ..................................................................................................................... 15
                                     Table 5:    Autoimmune Disorders Therapeutics Market, Treatment Usage Patterns (millions),
                                                 2002–2010 ..................................................................................................................... 16
                                     Table 6:    Autoimmune Disorders Therapeutics Market, Treatment Usage Patterns (millions),
                                                 2010–2017 ..................................................................................................................... 17
                                     Table 7:    Autoimmune Disorders Therapeutics Market, Global, Revenue Analysis by Geography
                                                 ($bn), 2002–2010 ........................................................................................................... 18
                                     Table 8:    Autoimmune Disorders Therapeutics Market, Global, Revenue Analysis by Geography
                                                 ($bn), 2010–2017 ........................................................................................................... 19
                                     Table 9:    Autoimmune Disorders Therapeutics Market, The US, Revenue ($bn), 2002–2010...... 20
                                     Table 10:   Autoimmune Disorders Therapeutics Market, The US, Revenue ($bn), 2010–2017...... 20
                                     Table 11:   Autoimmune Disorders Therapeutics Market, The US, Annual Cost of Treatment ($),
                                                 2002–2010 ..................................................................................................................... 21
                                     Table 12:   Autoimmune Disorders Therapeutics Market, The US, Annual Cost of Treatment ($),
                                                 2010–2017 ..................................................................................................................... 21
                                     Table 13:   Autoimmune Disorders Therapeutics Market, The US, Treatment Usage Patterns
                                                 (millions), 2002–2010 ..................................................................................................... 22
                                     Table 14:   Autoimmune Disorders Therapeutics Market, The US, Treatment Usage Patterns
                                                 (millions), 2010–2017 ..................................................................................................... 22
                                     Table 15:   Autoimmune Disorders Therapeutics Market, Top Five Countries of Europe, Revenue
                                                 ($bn), 2002–2010 ........................................................................................................... 23
                                     Table 16:   Autoimmune Disorders Therapeutics Market, Top Five Countries of Europe, Revenue
                                                 Forecasts ($bn), 2010–2017 .......................................................................................... 23
                                     Table 17:   Autoimmune Disorders Therapeutics Market, Top Five Countries of Europe, Revenue
                                                 ($bn), 2002–2010 ........................................................................................................... 24
                                     Table 18:   Autoimmune Disorders Therapeutics Market, Top Five Countries of Europe, Revenue
                                                 Forecasts ($bn), 2010–2017 .......................................................................................... 24
                                     Table 19:   Autoimmune Disorders Therapeutics Market, Top Five Countries of Europe, Annual Cost
                                                 of Treatment ($), 2002–2010 ......................................................................................... 25
                                     Table 20:   Autoimmune Disorders Therapeutics Market, Top Five Countries of Europe, Annual Cost
                                                 of Treatment ($), 2010–2017 ......................................................................................... 25
                                     Table 21:   Autoimmune Disorders Therapeutics Market, Top Five Countries of Europe, Treatment
                                                 Usage Patterns (millions), 2002–2010 ........................................................................... 26
                                     Table 22:   Autoimmune Disorders Therapeutics Market, Top Five Countries of Europe, Treatment
                                                 Usage Patterns (millions), 2010–2017 ........................................................................... 27
                                     Table 23:   Autoimmune Disorders Therapeutics Market, Japan, Revenue ($bn), 2002–2010 ........ 28
                                     Table 24:   Autoimmune Disorders Therapeutics Market, Japan, Revenue Forecast ($bn), 2010–
                                                 2017 ............................................................................................................................... 28
                                     Table 25:   Autoimmune Disorders Therapeutics Market, Japan, Annual Cost of Treatment ($),
                                                 2002–2010 ..................................................................................................................... 29
                                     Table 26:   Autoimmune Disorders Therapeutics Market, Japan, Annual Cost of Treatment ($),
                                                 2010–2017 ..................................................................................................................... 29
                                     Table 27:   Autoimmune Disorders Therapeutics Market, Japan, Treatment Usage Patterns
                                                 (millions), 2002–2010 ..................................................................................................... 30
                                     Table 28:   Autoimmune Disorders Therapeutics Market, Japan, Treatment Usage Patterns
                                                 (millions), 2010–2017 ..................................................................................................... 31
                                     Table 29:   Rheumatoid Arthritis Therapeutics Market, Global, Revenue ($bn), 2002–2010 ........... 32
                                     Table 30:   Rheumatoid Arthritis Therapeutics Market, Global, Revenue Forecast ($bn), 2010–2017
                                                 ....................................................................................................................................... 33
                                     Table 31:   Rheumatoid Arthritis Therapeutics Market, Global, Revenue Analysis by Geography
                                                 ($m), 2002–2010 ............................................................................................................ 34
                                     Table 32:   Rheumatoid Arthritis Therapeutics Market, Global, Revenue Analysis by Geography
                                                 ($m), 2010–2017 ............................................................................................................ 34
                                     Table 33:   Rheumatoid Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002–
                                                 2010 ............................................................................................................................... 37




Autoimmune Disorders Therapeutics Market to 2017 - Launch of                                                             GBIHC147MR /Published APR 2012
Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis                                                                                         Page 6
and Systemic Lupus Erythematosus Therapeutic Segments                               © GBI Research. This report is a licensed product and is not to be copied,
                                                                                                                    reproduced, shared or resold in any form
                                     Table 34: Rheumatoid Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010–
                                               2017 ............................................................................................................................... 37
                                     Table 35: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions),
                                               2002–2010 ..................................................................................................................... 38
                                     Table 36: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions),
                                               2010–2017 ..................................................................................................................... 38
                                     Table 37: Multiple Sclerosis Therapeutics Market, Global, Revenue ($bn), 2002–2010 ................ 42
                                     Table 38: Multiple Sclerosis Therapeutics Market, Global, Revenue Forecast ($bn), 2010–2017 . 43
                                     Table 39: Multiple Sclerosis Therapeutics Market, Global, Revenue Analysis by Geography ($m),
                                               2002–2010 ..................................................................................................................... 44
                                     Table 40: Multiple Sclerosis Therapeutics Market, Global, Revenue Analysis by Geography ($m),
                                               2010–2017 ..................................................................................................................... 44
                                     Table 41: Multiple Sclerosis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002–
                                               2010 ............................................................................................................................... 47
                                     Table 42: Multiple Sclerosis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010–
                                               2017 ............................................................................................................................... 47
                                     Table 43: Multiple Sclerosis Therapeutics Market, Global, Treatment Usage Patterns (thousands),
                                               2002–2010 ..................................................................................................................... 48
                                     Table 44: Multiple Sclerosis Therapeutics Market, Global, Treatment Usage Patterns (thousands),
                                               2010–2017 ..................................................................................................................... 49
                                     Table 45: Psoriasis Therapeutics Market, Global, Revenue ($bn), 2002–2010 ............................. 52
                                     Table 46: Psoriasis Therapeutics Market, Global, Revenue Forecast ($bn), 2010–2017 .............. 52
                                     Table 47: Psoriasis Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002–
                                               2010 ............................................................................................................................... 53
                                     Table 48: Psoriasis Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2010–
                                               2017 ............................................................................................................................... 54
                                     Table 49: Psoriasis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002–2010 ....... 56
                                     Table 50: Psoriasis Therapeutics Market, Global, Annual Cost of Treatment($), 2010–2017 ........ 56
                                     Table 51: Psoriasis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002–2010
                                               ....................................................................................................................................... 57
                                     Table 52: Psoriasis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010–2017
                                               ....................................................................................................................................... 57
                                     Table 53: Inflammatory Bowel Disease Therapeutics Market, Global, Revenue ($bn), 2002–2010
                                               ....................................................................................................................................... 60
                                     Table 54: Inflammatory Bowel Disease Therapeutics Market, Global, Revenue Forecast ($bn),
                                               2010–2017 ..................................................................................................................... 60
                                     Table 55: Inflammatory Bowel Disease Therapeutics Market, Global, Revenue Analysis by
                                               Geography ($m), 2002–2010 ......................................................................................... 61
                                     Table 56: Inflammatory Bowel Disease Therapeutics Market, Global, Revenue Analysis by
                                               Geography ($m), 2010–2017 ......................................................................................... 62
                                     Table 57: Inflammatory Bowel Disease Therapeutics Market, Global, Annual Cost of Treatment
                                               ($), 2002–2010 ............................................................................................................... 65
                                     Table 58: Inflammatory Bowel Disease Therapeutics Market, Global, Annual Cost of Treatment
                                               ($), 2010–2017 ............................................................................................................... 65
                                     Table 59: Inflammatory Bowel Disease Therapeutics Market, Global, Treatment Usage Patterns
                                               (thousands), 2002–2010 ................................................................................................ 66
                                     Table 60: Inflammatory Bowel Disease Therapeutics Market, Global, Treatment Usage Patterns
                                               (thousands), 2010–2017 ................................................................................................ 67
                                     Table 61: Systemic Lupus Erythematosus Therapeutics Market, Global, Revenue ($m), 2002–
                                               2010 ............................................................................................................................... 70
                                     Table 62: Systemic Lupus Erythematosus Therapeutics Market, Global, Revenue Forecasts ($m),
                                               2010–2017 ..................................................................................................................... 70
                                     Table 63: Systemic Lupus Erythematosus Therapeutics Market, Global, Revenue Analysis by
                                               Geography ($m), 2002–2010 ......................................................................................... 71
                                     Table 64: Systemic Lupus Erythematosus Therapeutics Market, Global, Revenue Analysis by
                                               Geography ($m), 2010–2017 ......................................................................................... 72
                                     Table 65: Systemic Lupus Erythematosus Therapeutics Market, Global, Annual Cost of Treatment
                                               ($), 2002–2010 ............................................................................................................... 74
                                     Table 66: Systemic Lupus Erythematosus Therapeutics Market, Global, Annual Cost of Treatment
                                               ($), 2010–2017 ............................................................................................................... 74
                                     Table 67: Systemic Lupus Erythematosus Therapeutics Market, Global, Treatment Usage Patterns
                                               (thousands), 2002–2010 ................................................................................................ 75
                                     Table 68: Systemic Lupus Erythematosus Therapeutics Market, Global, Treatment Usage Patterns
                                               (thousands), 2010–2017 ................................................................................................ 76


Autoimmune Disorders Therapeutics Market to 2017 - Launch of                                                                GBIHC147MR /Published APR 2012
Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis                                                                                            Page 7
and Systemic Lupus Erythematosus Therapeutic Segments                                  © GBI Research. This report is a licensed product and is not to be copied,
                                                                                                                       reproduced, shared or resold in any form
                                     Table 69: Autoimmune Disorders Therapeutics Market, Global, Pipeline Analysis, New Drug
                                               Application Filed Molecules, 2011 .................................................................................. 82
                                     Table 70: Autoimmune Disorders Therapeutics Market, Global, Pipeline Analysis, Phase III, 2011
                                               ....................................................................................................................................... 85
                                     Table 71: Autoimmune Disorders Therapeutics Market, Global, Pipeline Analysis, Phase II, 2011
                                               ..................................................................................................................................... 107
                                     Table 72: Autoimmune Disorders Therapeutics Market, Global, Pipeline Analysis, Phase I, 2011
                                               ..................................................................................................................................... 115
                                     Table 73: Autoimmune Disorders Therapeutics Market, Global, Pipeline Analysis, Preclinical
                                               Phase, 2011 ................................................................................................................. 118
                                     Table 74: Autoimmune Disorders Therapeutics Market, Global, Pipeline Analysis, Discovery
                                               Phase, 2011 ................................................................................................................. 126
                                     Table 75: Autoimmune Disorders Therapeutics Market, Global, Deals by Type, (%), 2009-2011 148
                                     Table 76: Autoimmune Disorders Therapeutics Market, Global, M&A Deals by Indication, 2009-
                                               2011 ............................................................................................................................. 149
                                     Table 77: Autoimmune Disorders Therapeutics Market, Global, Number of M&A Deals, 2009-2011
                                               ..................................................................................................................................... 150
                                     Table 78: Autoimmune Disorders Therapeutics Market, Global, M&A Deals by Deal Type (%),
                                               2009-2011 .................................................................................................................... 151
                                     Table 79: Autoimmune Disorders Therapeutics Market, Global, M&A Deals, by Value ($m), 2009-
                                               2011 ............................................................................................................................. 152
                                     Table 80: Autoimmune Disorders Therapeutics Market, Global, Number of Co-Development Deals,
                                               2009-2011 .................................................................................................................... 156
                                     Table 81: Autoimmune Disorders Therapeutics Market, Global, Co-Developments Deals by Value,
                                               2009-2011 .................................................................................................................... 157
                                     Table 82: Autoimmune Disorders Therapeutics Market, Global, Co-Development Deals by
                                               Geography, 2009-2011 ................................................................................................ 158
                                     Table 83: Autoimmune Disorders Therapeutics Market, Global, Co-development Deals by
                                               Geography, 2009-2011 ................................................................................................ 159
                                     Table 84: Autoimmune Disorders Therapeutics Market, Global, Licensing Agreements by
                                               Indication, 2009-2011................................................................................................... 164
                                     Table 85: Autoimmune Disorders Therapeutics Market, Global, Licensing Agreements by
                                               Indication (%), 2009-2011 ............................................................................................ 164
                                     Table 86: Autoimmune Disorders Therapeutics Market, Global, Licensing Agreements by Value,
                                               2009-2011 .................................................................................................................... 165
                                     Table 87: Autoimmune Disorders Therapeutics Market, Licensing Deals by Geography, 2009-2011
                                               ..................................................................................................................................... 167




Autoimmune Disorders Therapeutics Market to 2017 - Launch of                                                                GBIHC147MR /Published APR 2012
Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis                                                                                            Page 8
and Systemic Lupus Erythematosus Therapeutic Segments                                  © GBI Research. This report is a licensed product and is not to be copied,
                                                                                                                       reproduced, shared or resold in any form
                                     1.2       List of Figures
                                     Figure 1:   Autoimmune Disorders Therapeutics Market, Global, Revenue Forecasts ($bn), 2002–
                                                2017 ............................................................................................................................... 14
                                     Figure 2: Autoimmune Disorders Therapeutics Market, Global, Annual Cost of Treatment ($),
                                                2002–2017 ..................................................................................................................... 15
                                     Figure 3: Autoimmune Disorders Therapeutics Market, Treatment Usage Patterns (millions),
                                                2002–2017 ..................................................................................................................... 16
                                     Figure 4: Autoimmune Disorders Therapeutics Market, Global, Revenue Analysis by Geography
                                                ($bn), 2002–2017 ........................................................................................................... 18
                                     Figure 5: Autoimmune Disorders Therapeutics Market, The US, Revenue ($bn), 2002–2017...... 19
                                     Figure 6: Autoimmune Disorders Therapeutics Market, The US, Annual Cost of Treatment ($),
                                                2002–2017 ..................................................................................................................... 20
                                     Figure 7: Autoimmune Disorders Therapeutics Market, The US, Treatment Usage Patterns
                                                (millions), 2002–2017 ..................................................................................................... 21
                                     Figure 8: Autoimmune Disorders Therapeutics Market, Top Five Countries of Europe, Revenue
                                                Forecasts ($bn), 2002–2017 .......................................................................................... 23
                                     Figure 9: Autoimmune Disorders Therapeutics Market, Top Five Countries of Europe, Revenue
                                                Forecasts ($bn), 2002–2017 .......................................................................................... 24
                                     Figure 10: Autoimmune Disorders Therapeutics Market, Top Five Countries of Europe, Annual Cost
                                                of Treatment ($), 2002–2017 ......................................................................................... 25
                                     Figure 11: Autoimmune Disorders Therapeutics Market, Top Five Countries of Europe, Treatment
                                                Usage Patterns (millions), 2002–2017 ........................................................................... 26
                                     Figure 12: Autoimmune Disorders Therapeutics Market, Japan, Revenue Forecast ($bn), 2002–
                                                2017 ............................................................................................................................... 28
                                     Figure 13: Autoimmune Disorders Therapeutics Market, Japan, Annual Cost of Treatment ($),
                                                2002–2017 ..................................................................................................................... 29
                                     Figure 14: Autoimmune Disorders Therapeutics Market, Japan, Treatment Usage Patterns
                                                (millions), 2002–2017 ..................................................................................................... 30
                                     Figure 15: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2002–
                                                2017 ............................................................................................................................... 32
                                     Figure 16: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Analysis by Geography
                                                ($m), 2002–2017 ............................................................................................................ 33
                                     Figure 17: Rheumatoid Arthritis Therapeutics Market, Global, Branded & Generic Market Share
                                                (%), 2010 and 2017........................................................................................................ 35
                                     Figure 18: Rheumatoid Arthritis Therapeutics Market, Rheumatoid Arthritis, Treatment Algorithm 36
                                     Figure 19: Rheumatoid Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002–
                                                2017 ............................................................................................................................... 36
                                     Figure 20: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions),
                                                2002–2017 ..................................................................................................................... 37
                                     Figure 21: Rheumatoid Arthritis Therapeutics Market, Drivers and Barriers ................................... 39
                                     Figure 22: Multiple Sclerosis Therapeutics Market, Global, Revenue Forecasts ($bn), 2002–201742
                                     Figure 23: Multiple Sclerosis Therapeutics Market, Global, Revenue Analysis by Geography ($m),
                                                2002–2017 ..................................................................................................................... 43
                                     Figure 24: Multiple Sclerosis Therapeutics Market, Global, Branded & Generic Market Share (%),
                                                2010 and 2017 ............................................................................................................... 45
                                     Figure 25: Multiple Sclerosis Therapeutics Market, Multiple Sclerosis, Treatment Algorithm.......... 46
                                     Figure 26: Multiple Sclerosis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002–
                                                2017 ............................................................................................................................... 47
                                     Figure 27: Multiple Sclerosis Therapeutics Market, Global, Treatment Usage Patterns (thousands),
                                                2002–2017 ..................................................................................................................... 48
                                     Figure 28: Multiple Sclerosis Therapeutics Market, Drivers and Barriers ........................................ 50
                                     Figure 29: Psoriasis Therapeutics Market, Global, Revenue Forecasts ($bn), 2002–2017 ............ 52
                                     Figure 30: Psoriasis Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002–
                                                2017 ............................................................................................................................... 53
                                     Figure 31: Psoriasis Therapeutics Market, Global, Branded & Generic Market Share (%), 2010 and
                                                2017 ............................................................................................................................... 54
                                     Figure 32: Psoriasis Therapeutics Market, Psoriasis, Treatment Algorithm .................................... 55
                                     Figure 33: Psoriasis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002–2017 ....... 55
                                     Figure 34: Psoriasis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002–2017
                                                ....................................................................................................................................... 56
                                     Figure 35: Psoriasis Therapeutics Market, Drivers and Barriers ..................................................... 58
                                     Figure 36: Inflammatory Bowel Disease Therapeutics Market, Global, Revenue Forecasts ($bn),
                                                2002–2017 ..................................................................................................................... 60



Autoimmune Disorders Therapeutics Market to 2017 - Launch of                                                                GBIHC147MR /Published APR 2012
Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis                                                                                            Page 9
and Systemic Lupus Erythematosus Therapeutic Segments                                  © GBI Research. This report is a licensed product and is not to be copied,
                                                                                                                       reproduced, shared or resold in any form
                                     Figure 37: Inflammatory Bowel Disease Therapeutics Market, Global, Revenue Analysis by
                                                Geography ($m), 2002–2017 ......................................................................................... 61
                                     Figure 38: Inflammatory Bowel Disease Therapeutics Market, Global, Branded & Generic Market
                                                Share (%), 2010 and 2017 ............................................................................................. 62
                                     Figure 39: Inflammatory Bowel Disease Therapeutics Market, Ulcerative Colitis, Treatment
                                                Algorithm ........................................................................................................................ 63
                                     Figure 40: Inflammatory Bowel Disease Therapeutics Market, Crohn’s Disease, Treatment
                                                Algorithm ........................................................................................................................ 64
                                     Figure 41: Inflammatory Bowel Disease Therapeutics Market, Global, Annual Cost of Treatment
                                                ($), 2002–2017 ............................................................................................................... 65
                                     Figure 42: Inflammatory Bowel Disease Therapeutics Market, Global, Treatment Usage Patterns
                                                (thousands), 2002–2017 ................................................................................................ 66
                                     Figure 43: Inflammatory Bowel Disease Therapeutics Market, Global, Drivers and Barriers .......... 68
                                     Figure 44: Systemic Lupus Erythematosus Therapeutics Market, Global, Revenue Forecasts ($m),
                                                2002–2017 ..................................................................................................................... 70
                                     Figure 45: Systemic Lup
				
DOCUMENT INFO
Shared By:
Tags:
Stats:
views:53
posted:6/6/2012
language:English
pages:183
Description: The report provides insights into autoimmune disease therapeutics market until 2017. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. The report provides in-depth analysis of the main autoimmune diseases, which are Rheumatoid Arthritis (RA), Multiple Sclerosis (MS), Psoriasis, Inflammatory Bowel Disease (IBD) including Crohn’s Disease (CD) and Ulcerative Colitis (UC), and Systemic Lupus Erythematosus (SLE). The report also gives the share of generic drugs in global autoimmune diseases, as well as in each indication’s market. It examines global autoimmune diseases treatment usage patterns and the geographical distribution of autoimmune diseases and the markets in the US, the top five countries of Europe, and Japan. The report also includes insights into the R&D product pipeline and explores the competitive landscape with profiles of major players. Finally, it includes analysis of Mergers and Acquisitions (M&A) and licensing agreements that have taken place in autoimmune diseases therapeutics market from 2009 to 2011.
BUY THIS DOCUMENT NOW PRICE: $3500 100% MONEY BACK GUARANTEED
PARTNER GBI Research
GBI Research is a market-leading provider of business intelligence reports. GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders’ insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs. Headquartered in the UK, the company has branches in the US and Asia, and provides world class client support and service.